Shares of Cassava Sciences Inc. dropped more than 10% in the extended session Thursday after announcing a settlement with U.S. securities regulators, who had charged the pharma company and two former executives for “misleading claims” about an Alzheimer’s clinical trial.
More Stories
China ETFs set for best week on record after Beijing fires policy ‘bazooka’ to boost economy. Is it time to jump in?
China ETFs have surged on the back of a blitz of stimulus measures by the country’s government to revive the...
This company had $1 billion in quarterly AI bookings — and it’s not a chip maker
Accenture’s stock rallied toward a six-month high Thursday, after the management consultant got back to beating earnings expectations and continued...
Presidential race’s winner may not be clear on election night. Here’s how investors can prepare.
The winner of the tight White House race won’t be determined on the night of Nov. 5, a UBS strategist...
Higher corporate taxes sinking the S&P 500 isn’t investors’ biggest worry
About half of large U.S. corporations don’t pay any income tax in an average year
These tips for investing in mutual funds and ETFs can heap profits on your plate
China stocks, energy sector and bonds see strong investor demand.
Costco’s stock slips as quarterly sales come up short
Shares of Costco Wholesale Corp. slipped after hours, after the membership warehouse retailer reported sales trends that came up shy...